News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Bristol Myers Squibb (NYSE:BMY) is facing a revived US$6.7b lawsuit after a federal appeals court reinstated claims tied to its Celgene acquisition. Plaintiffs allege the …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%MGO One Seven LLC significantly reduced its stake in Toll Brothers Inc. (NYSE:TOL) by selling 7,698 shares, cutting its holdings by 70.4%. Despite this, Toll Brothers surpassed quarterly earnings expectations with an EPS of $2.72 and revenue of $2.53 billion, even as revenue declined …
Milford Funds Ltd. has reduced its stake in Toll Brothers Inc. (NYSE:TOL) by selling 19,252 shares, retaining 335,735 shares valued at approximately $55.3 million. This comes as institutional investors collectively own 91.76% of the company, and several company executives, including COO Robert Parahus and …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Bristol-Myers Squibb stock has delivered a 38.1% gain over the past year, while valuation …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%This article analyzes Capitol Federal Financial Inc. (CFFN) using AI models to identify volatility zones as tactical triggers. It notes a neutral near- and mid-term outlook but a positive long-term bias, highlighting a 23.5:1 risk-reward setup. The analysis provides specific institutional trading strategies for …
Bristol Myers Squibb's drug, iberdomide (Zenbexus), has received accelerated FDA approval for treating multiple myeloma, making it the first FDA-approved cereblon-modulating (CELMoD) protein degrader. Zenbexus is indicated for use with Darzalex Faspro and dexamethasone in adults who have received at least one prior line …
This article from Investing.com reports on Autolus Therapeutics plc's Form 8K filing for August 11. It indicates that the company's stock, AUTL, is down 3.15%. The content primarily serves as a placeholder for the Form 8K information, alongside various market data and other unrelated …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Bristol Myers Squibb (BMY) is back in focus after the FDA granted accelerated approval for ZENBEXUS in a multiple myeloma combination regimen, introducing …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Toll Brothers, Inc. TOL is scheduled to report its third-quarter fiscal 2026 results on Aug. 18, after market close. In the last reported quarter, the company's adjusted earnings and total revenues topped the Zacks Consensus Estimate by 5.4% and 5.1%, respectively. Year over year, …
Skandinaviska Enskilda Banken AB (publ) has disclosed a beneficial ownership of 5.3% in Autoliv Inc., amounting to 3,893,610 shares represented by Swedish Depositary Receipts (SDRs). This filing, a SCHEDULE 13G, indicates the bank has sole voting and dispositive power over these shares. The ownership …
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 15,000,000 American Depositary Shares (ADSs) in Autolus Therapeutics plc (AUTL), representing 5.64% of the outstanding ADSs. The shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as the …
Autolus Therapeutics (NASDAQ:AUTL) recently released strong quarterly results, with revenues exceeding expectations and statutory losses coming in lower than forecast. Following these results, analysts have upgraded their revenue and loss per share estimates for 2026, indicating increased optimism for the company's future performance. Despite …
Bristol Myers Squibb (BMS) received accelerated FDA approval for Zenbexus (iberdomide) for multiple myeloma, offering a new revenue stream as generics severely impact sales of its existing drugs, Revlimid and Pomalyst. Zenbexus is projected to achieve over $1 billion in annual earnings by 2031, …
Mariner Investment Group LLC recently acquired 10,000 shares of Toll Brothers Inc. (NYSE:TOL) worth approximately $1.65 million, increasing institutional ownership to 91.76%. Despite insider selling by the Chairman and COO, analysts maintain a "Moderate Buy" rating with an average price target of $164.88. Toll …
Bristol Myers Squibb has announced a new $2.3 billion multi-modal manufacturing campus in Houston, Texas, creating nearly 500 skilled jobs. This investment is part of BMS's $40 billion commitment to the US, aiming to accelerate the delivery of next-generation medicines. The campus's modular design …
Autoliv, Inc. (NYSE: ALV) (SSE: ALIV.sdb), a leader in automotive safety systems, announced its Board of Directors has declared a quarterly dividend of 87 cents for the third quarter of 2026. The dividend is payable on September 15, 2026, for NYSE-listed common stock holders …
Search by ticker symbol or company name and select a result to open its chart.